Viking Therapeutics (NASDAQ: VKTX)
$26.54
(-5.8%)
-$1.63
Price as of June 27, 2025, 3:58 p.m. ET
Viking Therapeutics Return vs. S&P
| 1 Year | 5 Year | 5 Year Annualized | Since IPO |
|---|
Viking Therapeutics Company Info
Viking Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of therapies for metabolic and endocrine disorders. The company was founded by Brian Lian and Michael A. Dinerman on September 24, 2012 and is headquartered in San Diego, CA.
News & Analysis
The Fool has written over 200 articles on Viking Therapeutics.
Featured Article
Why This Weight Loss Drug Company's Stock Surged Today
Lee Samaha | Jun 26, 2025
Featured Article
3 Growth Stocks I'm Loading Up On
George Budwell | Jun 26, 2025
How to Invest in Ozempic
Rachel Warren | Jun 25, 2025
2 Biotech Stocks to Buy Before They Soar 84% and 240%, According to Certain Wall Street Analysts
Adria Cimino | Jun 21, 2025
How to Invest in GLP-1 Stocks
Rachel Warren | Jun 19, 2025
Missed Out on Eli Lilly's 480% Gains Over the Past 5 Years? These GLP-1 Stocks Still Have Plenty of Upside.
David Jagielski | Jun 18, 2025
1 Stock Down 34% This Year to Buy and Hold
Prosper Junior Bakiny | Jun 8, 2025
What Companies Does Johnson & Johnson Own?
Matt DiLallo | Jun 5, 2025
Valuation
Earnings Transcripts
Viking Therapeutics (VKTX) Q2 2022 Earnings Call Transcript
VKTX earnings call for the period ending June 30, 2022.
Motley Fool Transcribing | Jul 28, 2022
Viking Therapeutics (VKTX) Q1 2022 Earnings Call Transcript
VKTX earnings call for the period ending March 31, 2022.
Motley Fool Transcribing | Apr 28, 2022
Viking Therapeutics (VKTX) Q4 2021 Earnings Call Transcript
VKTX earnings call for the period ending December 31, 2021.
Motley Fool Transcribing | Feb 10, 2022
Viking Therapeutics (VKTX) Q3 2021 Earnings Call Transcript
VKTX earnings call for the period ending September 30, 2021.
Motley Fool Transcribing | Nov 4, 2021
Related Stocks
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.